Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial.

@article{Kaseb2012EfficacyOB,
  title={Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial.},
  author={Ahmed Kaseb and Elizabeth L Garrett-Mayer and Jeffrey S. Morris and Lianchun Xiao and Erpei Lin and Georgiana Onicescu and Manal M. Hassan and Hesham M. Hassabo and Michiko Iwasaki and F L Deaton and James L Abbruzzese and Melanie Byrne Thomas},
  journal={Oncology},
  year={2012},
  volume={82 2},
  pages={67-74}
}
OBJECTIVE A phase II study was performed to evaluate the efficacy and tolerability of bevacizumab and erlotinib in advanced hepatocellular carcinoma (HCC) patients, and to investigate clinical and molecular predictors of outcome. METHODS 59 patients with advanced HCC received 10 mg/kg i.v. of bevacizumab every 14 days and 150 mg p.o. of erlotinib daily. The primary endpoint was progression-free survival (PFS) at 16 weeks. Clinical characteristics and plasma biomarkers expression levels were… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 45 extracted citations

Interested in publishing with us ? Contact book

Hossain Chowdhury Mobaswar, Bhattacharya Sanchari, S Ghosh
2018
View 1 Excerpt

Radiation Therapy for Liver Tumors

Springer International Publishing • 2017

References

Publications referenced by this paper.
Showing 1-10 of 16 references

sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

A Hirata, S Ogawa, +4 authors M Ono
J Clin Oncol • 2009

Sorafenib in advanced hepatocellular carcinoma.

The New England journal of medicine • 2008

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2005

Similar Papers

Loading similar papers…